News

The new patent has a scheduled expiry date in 2028, not including any potential regulatory extensions. The HuCAL-derived, fully human antibody is currently being tested in a Phase

WEP has developed two proprietary biopolymer technologies, PolyPEG and GlycoPol. WEP has agreements with global pharmaceutical and biotechnology companies for the evaluation of PolyPEG or GlycoPol and the

GCS-100 is an inhibitor of galectin-3, a novel molecular target implicated in cancer and chronic organ failure. Galectin-3 plays a key role in the immune system’s response to

As per the termination, all rights to develop and commercialize the product were returned to the company in exchange for Talon’s right to receive certain royalty payments in

Under terms of the agreement, Genzyme will market and promote Veracyte’s Afirma Thyroid FNA Analysis, a novel approach for improved thyroid nodule diagnosis, in the US and, subsequently,

The Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment (PRESENT) study will enroll approximately 700 breast cancer patients. The

The new label identifies anti-JCV antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal leukoencephalopathy (PML). The new label

BBR has continued research in animal models verifying pharmacological properties of the CD14 molecule, the company said. The glycoprotein CD14 on the surface of human macrophages is important

The NSCLC trial evaluated four dose levels of IMO-2055 in combination with standard doses of Tarceva and Avastin in thirty-three patients. In the trial the patients were evaluable